Dr Reddy's Laboratories announces the launch of Cinacalcet Tablets in the US Market

Hyderabad, India and Princeton, NJ, USA. October 01, 2020 - Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets, approved by the U.S. Food and Drug Administration (USFDA). 
 
The Sensipar brand and generic market had U.S. sales of approximately $­­­­­312 million MAT for the most recent twelve months ending in July 2020 according to IQVIA Health*.
 
Dr. Reddy’s Cinacalcet Tablets are available in 30 mg, 60 mg, and 90 mg tablets in a bottle count size of 30.